N/A N=221 LBBAP Data Collection Registry
Bradycardia · Sinus Node Dysfunction · Heart Block
Primary: The Primary Safety Endpoint Evaluates Freedom From LBBAP Lead Related Serious Adverse Device Effects (SADEs). — 220 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
Fabry Disease
Primary: Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) — 2 Participants
Phase 4 N=262 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Episodic Migraine
Primary: Number of Participants With Adverse Events (AEs) — 130; 94 Participants
Phase 3 N=532 Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Efficacy of Sipuleucel-T Measured as the Percentage of Subjects Without Histological Reclassification (Gleason Group Upgrade). — 108; 48 Participants — p=0.4586
Phase 2 N=10 Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Metastatic Melanoma · Stage III Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Number of Participants With Immune-Related Response — 8 Participants
N/A N=196 Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
Metastatic Breast Cancer
Primary: Real World Tumor Response (rwTR) of All Participants (Adjusted by Normalized Inverse Probability of Treatment Weighting [nIPTW]) — 52.1; 46.2 Percentage of Participants
Phase 2 N=42 NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Suspected or Confirmed COVID-19
Primary: Amplicon Sequence Variants (ASVs) That Are Significantly Correlated With Variation in the Microbiome Data Between NBT-NM108 Group and Usual Care Only Group From Day 0 to…
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
Phase 4 N=659 BCG Vaccine for Health Care Workers as Defense Against COVID 19
Coronavirus · Coronavirus Infection · Coronavirus as the Cause of Diseases Classified Elsewhere
Primary: Number of New COVID 19 Infections — 25; 21 Participants
N/A N=122 Navio With Total Knee Arthroplasty
Total Knee Arthroplasty · Arthroplasty of Knee
Primary: Count of Participants With Post-operative Mechanical Alignment — 106; 9 Participants
N/A N=54 Faith-Based Toolbox for African Americans With Dementia
Alzheimer Disease · Dementia
Primary: Number of Participants Recruited Within the Goal of 12 Months — 14; 14; 13; 13 Participants
Phase 2 N=58 Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Phase 2 N=189 Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Stage III Non-small Cell Lung Cancer · Unresectable
Primary: Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents — 23.9; 35.0; 40.3 Percentage of…
N/A N=203 TeleHepC Treatment Trial
Hepatitis C
Primary: Viral Response — 63; 16 Participants
Phase 1 N=63 A Study of LY3002813 in Participants With Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 0; 2; 0 Participants